LucyDx is an early-stage medical technology company launched in February 2021 out of the FedTech Startup Studio Fall 2020 cohort with the purpose of commercializing a wearable diagnostic device for the early detection of diabetic retinopathy. Our team was carefully evaluated on several verticals and selected by FedTech with qualifications and expertise suitable for the commercialization of this particular technology based on our extensive experience in medical devices, diagnostics, hardware, software, firmware, and wearables. We have pinpointed a target market and validated demand through dozens of customer discovery interviews with various physicians, health care providers, educators, and diabetics making us a primarily a direct to consumer business. We have confirmed that our proposed application of the technology has an existing reimbursement (CPT) code and plans to be Medicare-eligible; hence, it can be reimbursable through many private health insurance plans. This technology is being licensed from governmental and educational institutions.We are driven by our success in the Mass Challenge 2021 program as Gold Award winners.